I N T E R N A T I O N A L S O C I E T Y O F
P H A R M A C O V I G I L A N C E
P h a r m a c o v i g i l a n c e -C u r r e n t a n d F u t u r e C h a l l e n g e s
4 T H A N N U A L M E E T I N G
(ii)
6 T H - 8 T H O C T O B E R , D U B L I N , I R E L A N D
V E N U E
The Conrad Hotel Dublin,
Earlsfort Terrace,
Dublin 2,
Ireland
Tel: +353 1 602 8900
Fax: +353 1 676 5424Email: [email protected] www.conradmeetings.com
The Conrad Dublin is located off St. Stephen's Green in the downtown commercial district, a few
minutes walk from the main shopping and cultural centres and is directly opposite the National
Concert Hall. The hotel is only minutes from the fashionable shopping area of Grafton Street
P L E A S E N O T E
Smoking is not permitted in any public areas at the meeting venue,
or in any public place in Ireland.
(iii)
C O N T E N T S
Organisers .....................................3
Welcome Address...........................4
At the Venue..................................5
Scientific Programme .....................7
Posterlist ........................................14
Social Programme ..........................19
General Information ......................20
1
P R E C E D I N G C O N F E R E N C E S
In 2000 the European Society of Pharmacovigilance changed its name to theInternational Society of Pharmacovigilance:
1993 Geneva, Switzerland1994 Rouen, France1995 Cambridge, England1996 Lisbon, Portugal1997 Berlin, Germany1998 Budapest, Hungary1999 Ankara, Turkey2000 Verona, Italy2001 Carthage-Tunis, Tunisia2002 Amsterdam, The Netherlands2003 Marrakesh, Morocco2004 Dublin, Ireland
I S O P E X E C U T I V E C O M M I T T E E
Giampaolo Velo, President ItalyChalbi Belkahia, Vice-President TunisiaNicholas Moore, Secretary General FranceBrian Edwards, Treasurer United KingdomJürgen Beckmann, GermanyAna Maria Corrêa-Nunes, PortugalIain Cockburn United KingdomRalph Edwards (Past President) SwedenKees van Grootheest The NetherlandsElisabeth Loupi FrancePaula Marquez Padorno SpainRonald Meyboom The NetherlandsMichel Ollagnier FranceRachida Soulaymani MoroccoRènè-Jean Royer (Honarary President) France
The aim of the International Society of Pharmacovigilance (ISoP) is to provide an international
forum for all those with an interest in the clinical and scientific aspects of drug safety- and not
only full-time pharmacovigilance professionals. Our society consists of members from industry,
governmental agencies, research and academic bodies.
For information about membership, please contact:International Society of Pharmacovigilance
PO Box 32 974,London SW19 8YG,
Phone/Fax: +44(0)20 82861888Email: [email protected]
Website: www.isoponline.org
2
O R G A N I Z E R S
ORGANIZING COMMITTEE (LOCAL)
Joan Gilvarry
Niamh Arthur
Deirdre McCarthy
Wendy Donoghue
SCIENTIFIC COMMITTEE
Jürgen Beckmann, Chairman
Niamh Arthur
Iain Cockburn
Joan Gilvarry
Paula Marquez Padorno
Thierry Trenque
POSTER PRIZE JURY
Sandeep Agarwal
Ana Maria Corrêa-Nunes
Kees van Grootheest
3
W E L C O M E A D D R E S S
Dear Colleagues,
It is with great pleasure that we welcome you to Ireland’s capital city, Dublin, to attend
the 4th Annual Meeting of the International Society of Pharmacovigilance.
We hope that you will enjoy your stay in this lovely, historic and vibrant city. The
venue for our meeting is centrally located near the heart of Georgian Dublin, while also
easily accessible to a beautiful nearby park and within easy reach of all the
recommended meeting hotels.
The Scientific Committee has taken account of feedback from the last meeting of ISoP
in Marrakesh, so we hope that the proposed scientific programme will be of great
interest to you.
The overall theme of the conference ‘Pharmacovigilance - Current and Future
Challenges’ has been chosen in order to cover a large range of topical and evolving
important pharmacovigilance issues. We hope you will find the conference stimulating,
educational and beneficial, as well as an opportunity to make new friends and renew
old friendships.
On behalf of the Organizing Committee, I look forward to meeting you in Dublin to
celebrate this important event and to enjoy our historic and charming city.
Niamh ArthurPresident of the Local Organizing Committee
4
A T T H E V E N U E
P R A C T I C A L I N F O R M A T I O N
Registration Desk
• The registration desk will be open every day from 8.00 a.m. until the end of all
scientific sessions and will provide:
• Conference material for registered participants
• On-site Conference registration
• Message service to and from participants
• Tickets for Conference Dinner
Bags and Badges:
• You will receive your conference badge when you register. Please wear it at
all times to identify you as a conference participant and for your coffee and
lunch breaks.
• You will also receive a delegates’ bag containing the conference brochure
and other useful information.
Internet access/e-mails:
• Access to the Internet will be available in the pre-function area during
meeting hours
Speakers’ room:
• Staff will be available in the Speakers’ Room (1st floor, Boardroom 1) for the
duration of the conference to assist with presentations etc.
• Speakers are requested to provide their presentation on diskette or CD Rom as early
as possible on the day of their presentation.
• The staff in the Speakers’ Room will also be happy to provide you with information
and leaflets on transportation, sightseeing etc. around Dublin.
Taxis:
• A taxi rank is situated just outside the hotel.
Please note that smoking is not permitted at any venue (meeting/social/buses/taxis etc.) in Ireland
5
M E E T I N G T I M E T A B L E
W E D N E S D A Y , O C T O B E R 6 , 2 0 0 4
12.00: Arrival and Registration
13.00-14.00: Lunch
14.00-17.15: Joint session with the 27th WHO National Centres Meeting
18.30-20.30: Welcome Reception, Chester Beatty Library, Dublin Castle
T H U R S D A Y , O C T O B E R 7 , 2 0 0 4
08.00-09.00: Registration
09.00-09.20: Opening Ceremony
09.20-11.00: Parallel Sessions 1 and A
11.20-13.00: Parallel Sessions 2 and B (including coffee break)
13.00-14.20: Lunch and poster session
14.20-16.00: Parallel Sessions 3 and C (including coffee break)
16.20-18.00: Parallel Sessions 4 and D
19.00-22.30: Conference dinner (Old Jameson Distillery, Smithfield, Dublin)
F R I D A Y , O C T O B E R 8 , 2 0 0 4
09.00-10.40: Parallel Sessions 5 and E
11.00-12.40: Parallel Sessions 6 and F (including coffee break)
12.40-14.00: Lunch and poster session
14.00-14.50: Overview of key meeting issues and awarding of poster prizes
14.50-15.40 Keynote Address
15.40-16.30: General Assembly, poster prize
16.30-17.00: Closing Session; Invitation to ISoP 2005
6
S C I E N T I F I C P R O G R A M M E
7
M E E T I N G R O O M L O C A T I O N
8
PlenaryHall
PlenaryHall
PlenaryHall
Ground FloorCONRAD BALLROOM
Liffey Dodder Dargle
W E D N E S D A Y , 6 T H O C T O B E R
P L E N A R Y H A L L
9
12.40 - 14.00 LUNCH
14.00 JO I N T SE S S I O N W I T H T H E WHO AN N U A L ME E T I N G O F
NAT I O N A L CE N T R E S
Dr Joan Gi lvarry , I r i sh Medic ines Board
Prof Vladimir Lepakhin, WHO Geneva
Prof Giampaolo Velo, Pres ident of ISoP
14.00-14.10 CH A I R P E R S O N’S IN T R O D U C T O RY RE M A R K S
14.10-15.00 1. KE Y N O T E A D D R E S S
‘The Mountain Peaks and Pitfal ls of being Spontaneous’
Professor S tephen Evans
15.00-15.15 CO F F E E BR E A K
15:15-15:30
15:30-16:15
16:15-16:45
16:45-17:00
17:00 -17:15
18:30 –20:30
20:00-22:30
Review of the preceding 27th Annual Meeting of National Centres
participating in the WHO International Drug Monitoring Programme
Dr Mary Couper, WHO Geneva
Survei l lance of ADRs - HIV drugs in Sweden
Dr L inda Morfe ld t , Karol inska Hospi ta l , Sweden
Mr Anders Sundström, Medical Products Agency, Sweden
Round Table discussion on key issues relat ing to topics from
the WHO meeting
Proposals for co-operation betweenWHO and ISoP for the
benefi t of world-wide drug safety and public health
Prof Vladimir Lepakhin
Closing Session of the 27th WHO Annual Meeting of National
Centres
Welcome Reception - Chester Beatty Library, Dublin Cast le
Meeting of the ISoP Executive Committee
10
T H U R S D A Y , 7 T H O C T O B E R
P L E N A R Y H A L L
SE S S I O N SP E A K E R S TI T L E
09.00-09.20 OP E N I N G SE S S I O N ISOP AN N U A L ME E T I N G (PL E N A RY HA L L)Mr. Pat O’Mahony, Chie f Execut ive Of f icer, IMB
Ms. Niamh Arthur, Phar macovigi lance Co-ordinator, IMBPr of . Giampaolo Ve lo , Uni Ver ona, Pr es ident o f ISoP
09.20-11.00
Chair :
Co-Chair
1. Medication errors
Prof. Ralph Edwards
Dr Thierry Trenque
11.20–13.00 2. Pharmacovigilance Planning
Chair : Dr. Abida Haq
Co-Chair : Dr. Priya Bahri
09:20-09:30
09:30-09:45
09:45 -10:00
10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00
R Edwards
R Edwards
P Caduff-Janosa
I Nnani
R Leone
D Chi
S Agarwal
Chairman’s introductory overview
WHO world alliance for patient safety
Medication errors in Switzerland: an analysis ofthe spontaneous adverse reaction reports receivedat the swissmedic pharmacovigilance centre
Counterfeit medicine; medication errorprone
Errors in drug therapy transmission fromdoctors to nurses: an hospital pilot study
Clinical pharmacist's role inpharmacovigilence in a cardiovascular wardof China
Medication errors in India
11:20-11:35
11:35-11:50
11:50 -12:05
12:05-12:20
12:20-12:30
12:30-13:00
X Kurz
C Martinez
S Shakir
P Bahri
A Haq
The ICH pharmacovigilance planning guidance
The General Practice Research Database-animportant resource for pharmacovigilance planning
The evidence base for drug withdrawals
An EMEA perspective on pharmacovigilance plans
Use of pharmacovigilance plans in non-ICHcountries
Discussion
14.20–16.00 3. Vaccine Vigi lance
Chair : Dr. Elisabeth Loupi
Co-Chair : Prof. Chalbi Belkahia
14:20-14:30
14:30-14:45
14:45-15:00
15:00 -15:15
15:15-15:35
15:35-16:00
E Loupi
K Hartmann
K Iskander
A Dodoo
U Mehta
K Connolly
Chairperson’s introductory overview
From signal detection to hypothesis testing ; facialparesis following intranasal flu immunisation
Increasing complexity of vaccine safety surveillancedatabases: the case for 'data mining
Safety monitoring of a new pentavalent vaccine inGhana’s Expanded Programme on Immunization (EPI)
Global overview of vaccine safety monitoring: progress,challenges and opportunities
Prediction of adverse events following immunisation(AEFI)
16 .20–18 .00 4. Depression and suicide as ADRs
Chair : Dr. David Coulter
Co-Chair Dr John F Connolly
16:20-16:40
16:40-17:00
17:00 -17:20
17:20-17:35
17:35-17:50
17:50-18:00
D Coulter
J F Connolly
I R Edwards
B Caffari
K. Kamagate
Depression and suicide as ADRs – an introduction
A psychiatrist’s view of depression and suicide asADRs
Data mining insights on SSRIs & suicide
SSRI adverse events in the italian population
Intoxication by medicinal plants in Abidjan: clinicaland ethnobotanical aspects
Discussion
11.00-11.20 CO F F E E BR E A K (Posters Displayed for Review)
13.00 – 14.20 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F TH U R S D AY PO S T E R S
16.00–16.20 CO F F E E BR E A K (PO S T E R S D I S P L AY E D F O R R E V I E W)
19.00–22.30 OF F I C I A L CO N F E R E N C E DI N N E R
11
T H U R S D A Y , 7 T H O C T O B E R
SY N D I C AT E RO O M S 1S T FL O O R ~ “DO D D E R/DA R G L E”
SE S S I O N SP E A K E R S TI T L E
09.20-11.00
Chair :
Co-Chair
A. Safety of new drugs used inmetabolic disorders in the elderly
Dr Kenneth Hartigan-go,
Prof Brian Sheppard
11.20–13.00 B. Benefit/risk of OTC analgesics
Chair : Prof Nicholas Moore
Co-Chair : Prof Jörg Hasford
09:20-09:40
09:40-10:00
10:00 -10:20
10:20-10:40
10:40-11:00
K Hartigan-go
D Coppola
L Wilton
H Berthold
L Wilton
Chairman’s introductory overview
Glimepiride and glibenclamide: summary of toxicepidermal necrolysis and Stevens Johnson Syndrome
The management and outcomes of specific adverse drugreactions in patients prescribed pioglitazone in primarycare in England; interim results
“Phossy jaw” revisited – do bisphosphonates cause“bisphossy jaws”?
Ophthalmological events in patients taking risedronate:follow up information in a prescription-event monitoringstudy
11:20-11:40
11:40-11:55
11:55 -12:10
12:10-12:25
12:25-12:40
12:40-13:00
N Moore
A Bijl
M Voelker
L Bensouda
MOllagnier
J Hasford
Chairman’s introductory overview
Anaphylactic reactions to over the counter (OTC)analgesics, particularly propyphenazone-combinations
Safety and tolerability of aspirin in randomisedcontrolled clinical trials
Is the risk of upper gastrointestinal bleedingincreased with NSAIDs used as analgesics, inchildren : a case crossover study.
Aryl carboxylic non-steroidal inflammatory drug (AC)induced serious renal adverse effects result of afrench national survey
Safety and appropriateness of use of a low-dose OTCNSAID: methodological issues and results of apharmacy-based cohort study
14 .20–16 .00 C.Training & Communication in Pharmacovigilance
Chair : Prof Giampaolo Velo
Co-Chair : Dr Paula Marquez
14:20-14:35
14:35-14:55
14:55-15:10
15:10-15:25
15:25-15:45
15:45-16:00
G Velo
S Olsson
G PPolimeni
C Anton
P Marquez
Issues relating to drugs, the media and communication
Ten years of international pharmacovigilance trainingby the Uppsala Monitoring Centre
www.ecm.farmacovigilanza.org: an Italian website forCME in pharmacovigilance
Does informing GPs about common adverse drugreactions (ADRs) influence ADR reporting rates?
The next steps in the ISoP education & Training Project
Discussion
16 .20–18 .00 D. Surrogate Markers in Pharmacovigilance
Chair : Dr Jürgen Beckmann
Co-Chair Dr Mary Teeling
16:20-16:40
16:40-17:00
17:00-17:20
17:20-17:40
17:40-17:55
17:55-18:00
M Teeling
R Shah
J Beckmann
B Sachs
L Wilton
Co-chairperson’s introductory overview
QT-prolongation
APC-resistance as a surrogate marker for drugthrombogenicity
The lymphocyte transformation test (LTT) as a surrogatemarker for drug sensitization
The management and outcomes of specific adverse drugreactions in patients prescribed rosiglitazone in primarycare in England
Discussion
11.00-11.20 CO F F E E BR E A K (Posters Displayed for Review)
13.00 – 14.20 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F TH U R S D AY PO S T E R S
16.00–16.20 CO F F E E BR E A K (PO S T E R S D I S P L AY E D F O R R E V I E W)
19.00–22.30 OF F I C I A L CO N F E R E N C E DI N N E R
12
F R I D A Y , 8 T H O C T O B E R
P L E N A R Y H A L L
SE S S I O N SP E A K E R S TI T L E
11.00–12.40 6. Future challenges in pharmacovigilance
Chair : Prof. Ingemar Persson
Co-Chair : Prof. Paul McKeigue
14.00–14.20 Overview of Key Meeting IssuesDr. Jürgen Beckmann
14.20-14.50 Award of poster prizes and short scienti f ic presentat ions by the winners
14.50-15.40 11. Keynote address (Plenary Hall)“The impact of the National Institute for Clinical Excellence (NICE) on drug safety” Prof Sir Mike Rawlins, UK
15.40-16.30 General Assembly of ISoP
16.30-17.00 Invitat ion to the ISoP 2005 Annual Meeting in Manila , Phil ippines
Closing Session
Ms. Niamh Ar thur, Dr. Kenneth Har t igan-go, Prof . Giampaolo Velo
09.00-10.40 5. Enhancing ADR reporting
Chair : Dr. Ronald Meyboom
Co-Chair : Prof. Sandeep Agarwal
09:00-09:10
09:10-09:25
09:25-10:40
10:40-10:55
10:55-11:10
11:10-10:25
10:25-10:40
R Meyboom
L Borsellino
F Salvo
GDalmacion
M Ferreira-Herdeiro
G Polimeni
E VanPuijenbroek
Chairmans’ introductory overview
Organization of regional centres ofpharmacovigilance: the example of Sicily(Italy)
Signal detection in spontaneous reporting Database: data from GIF, an italian inter-regional database
Pharmacovigilance in Public Health programs:do we need it?
Physician reporting of adverse drug reactions:a case-control study in Portugal.
Feedback information to reporters as a toolfor continuing education in pharmacovigilance
Time required for follow up information onspontaneous reports
11:00-11:10
11:10-11:30
11:30-11:55
11:55 -12:15
12:15-12:35
12:35-12:40
I Persson
L Middleton
P McKeigue
E. JaquenoudSirot
R Edwards
Chairman’s introductory overview
Recent developments in pharmacogenetics andpotential applications in pharmacovigilance
EUDRAGENE and related projects
TDM and pharmacogenetic tests as tools inpharmacovigilance
Knowledge finding in IMS disease analyzerMediplus UK database – effective data mining inlongitudinal patient safety data
Discussion
10.40-11.00 CO F F E E BR E A K (Posters Displayed for Review)
12.40 – 14.00 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F FR I D AY PO S T E R S
13
F R I D A Y , 8 T H O C T O B E R
SY N D I C AT E RO O M S 1S T F L O O R - “DO D D E R/DA R G L E”
SE S S I O N SP E A K E R S TI T L E
11.00–12.40 F. Patient-related risk determinants (excl drug-druginteractions)
Chair : Prof. Rudolf Stoller
Co-Chair : Ms Sevgi Öksüz
09.00-10.40 E. Heparin-induced thrombocytopenia and other haematological ADRs
Chair : Prof Andreas Greinacher
Co-Chair : Prof. Saad Shakir
09:00-09:30
09:30-09:45
09:45 -10:00
10:00-10:15
10:15-10:25
10:25-10:40
A Greinacher
G Traversa
F. Haramburu
V Gras-Champel
V Gras-Champel
R Meyboom
Drug-induced immune thrombocytopenia withspecial focus on heparin-inducedthrombocytopenia
Thrombocytopenia associated with non-cytotoxic drug use: a prospective case-controlstudy
Drug-induced haemorrhage in communitypractice
Risk factors for bleeding in patients with oralanticoagulant treatment (OAT) andsupratherapeutic international normalised ratio(INR) when hospitalised
Can colchicine potentiate the anticoagulanteffect of fluindione ?
Reports of leukaemia and lymphoma duringthe use of clozapine and other atypicalneuroleptics
11:00-11:10
11:10-11:25
11:25 -11:40
11:40-11:55
11:55-12:10
12:10-12:25
12:25-12:40
R Stoller
A Zaïem
K Aouam
M Tuccori
M Smadja
A Conforti
Chairman’s introductory overview
Adverse drug reactions in elderly: results ofTunisian national centre of pharmacovigilance
Clinical findings of acetylsalicylic/ non-steroidalanti-inflammatory drugs-induced urticaria
Haemorrhagic gastritis and severe bleedingfollowing rofecoxib administration: a case report
Is weekly-administration of paclitaxel less toxicthan 3-weekly? A prospective pharmacovigilancestudy based on patient’s and physician’s reports.
Ciclosporin and serious intestinal disorders
Discussion
10.40-11.00 CO F F E E BR E A K (Posters Displayed for Review)
12.40 – 14.00 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F FR I D AY PO S T E R S
I S O P P O S T E R P R I Z E
Prizes will be awarded for the three best posters at the ISoP Annual Meeting. All posters accepted for the Annual Meeting are eligible for a prize.
Posters will be displayed in the Alexandra Room on the ground floor on Thursday 7thOctober and Friday 8th October 2004 between 09:00 and close of the meeting each day.
Presenters are asked to put up their poster between 08:00 and 09:00 on the appropriate dayand staff will be available in the Alexandra Room to help during this time.
Presenters are also asked to be in attendance of their posters between 12.30 and 14:00 onthe relevant day.
Thursday 7th October 2004
05, 20, 25, 30, 55, 60, 70, 80, 85, 95, 100, 110, 117, 125, 135, 150, 185, 205, 215, 220, 225,
230, 260, 275, 285, 305, 310, 315, 360, 365, 370, 375, 380, 385, 420, 425, 410, 430, 440, 460,
475, 476, 477, 485, 505, 515, 520, 570, 580, 585, 615, 635, 645, 650, 665, 670, 690, 700, 705,
710, 715, 725, 750
Friday 8th October 200415, 40, 105, 120, 190, 195, 235, 240, 250, 255, 290, 300, 325, 330, 340, 345, 350, 390, 395,400, 405, 445, 465, 470, 510, 540, 555, 560, 565, 595, 620, 625, 640, 655, 675, 680, 685, 695,º720, 755
14
P005 HYPERTENSION INDUCED BY CYCLOSPORIN IN RENAL TRANSPLANTM.A. Ait El Cadi, Y. Khabbal, M. Aghrouch, S. Soussi Tanani, N.O. Ouzeddoun, Y. Cherrah
P015 HOW TO INCREASE THE SPONTANEOUS REPORTING IN ARGENTINA?L. Alesso, R. Herrera, C. Saidman, P. Lipszyc,R. Iannantuono
P020 LACK OF EFFICACY IN ANAESTHETICSL. Alesso, R. Herrera, V. Costamagna, G. Campos
P025 MEDICATION ERRORS IN ANAESTHESIAEL. Alesso, E. Casini, E. Gallino, P. Lipszyc, C. Chiale,M. Limeres, C. Saidman
P030 PHARMACODYNAMIC AND PHARMACOKINETICINSIGHTS IN HEADACHE PATIENTS WITH DRUG OVERUSEB. Alfredo, A. Capasso, S. Salomone
P040 ANALYSIS OF ADR REPORTS FOR YEAR 2003P.S. Ang, B.H. Tan, K.N. Ting, Ch.L. Chan
P55 AGREEMENT OF EXPERT JUDGMENT IN ASSESSMENT OF CAUSALITY OF ADVERSE DRUG REACTIONSY.A. Arimone, B.B. Bégaud, G.M. Miremont-Salamé,F.H. Haramburu, A.F. Fourrier-Réglat
P60 INTER-EXPERT AGREEMENT ABOUT SEVEN OPERATIONAL CRITERIA FOR CAUSALITY ASSESSMENT OF ADVERSE DRUG REACTIONSY.A. Arimone, B.B. Bégaud, A.F. Fourrier-Réglat,F.H. Haramburu, G.M. Miremont-Salamé
P70 SPONTANEOUS REPORTING OF ADRS ASSOCIATEDWITH HERBAL MEDICINES: A CROSS-SECTIONAL SURVEY OF NATIONAL PHARMACOVIGILANCE CENTRES J. Barnes, A. Aggarwal
P80 A RARE DRUG REACTION TO METHOTREXATE AFTER TREATMENT FOR ECTOPIC PREGNANCY.Y. Benjelloun
P85 DRUG USE DURING PREGNANCY AND LACTATIONY. Benjelloun, F. Benzekri, A. Ansari, M. Taibi Ouazzani
P95 ALLERGIC VASCULITIS TO BETA LACTAMINSR. Benkirane, M. SBIHI, L. Alj, M.A. Sbihi,R. Soulaymani, Y. Khabbal
P100 DRUG INDUCED CUTANEOUS REACTIONS : RETROSPECTIVE ANALYSIS OF THE CASE REPORTSR. Benkiran, M. SBIHI, L. Alj, M.A. Sbihi, R. Soulaymani
P105 HEMOCHOLECYSTIS RESULTING FROM INTERACTION BETWEEN ANTICOAGULANT ANTIVITK AND CELECOXIBR. Benkirane, M. SBIHI, L. Alj, M.A. Sbihi, R. Soulaymani
P110 PROLONGED ARTERIAL HYPOTENSION FOLLOWING PROPOFOL INDUCTIONR. Benkirane, M. SBIHI, L. Al, M.A. Sbihi, Y. Khabbal,R. Soulaymani
P117 SEROTONIN SYNDROME INDUCED BY MIRTAZAPINE MONOTHERAPYrb Bertoli, M Tosi, G Vanini, P Caduff, A Cerny
P120 SERIOUS SIDE-EFFECTS OF BUPROPION. WHO IS AT RISK AMONG 524 000 EXPOSED PATIENTS?M.N. Beyens, S. Laporte, M. Ollagnier
15
P125 COPRESCRIPTION OF GASTROPROTECTIVE AGENTS AND SHIFTING BETWEEN DRUGS: IS THERE A DIFFERENCE BETWEEN TRADITIONAL NSAIDS AND COXIBS?C. Bianchi, I. Abraha, C. Romagnoli, G. Traversa
P135 ANALGESICS AND HEPATO-BILIARY INJURIES : A PHARMACOEPIDEMIOLOGICAL CASE/NON CASE STUDY.A. Bonneau, C. Remblier, M.C. Perault
P150 AGE AND GENDER DISTRIBUTION OF CUTANEOUS DRUG REACTIONS IN FRANCEH.B. Brocvielle, J.C.R. Roujeau, L.T. Thomas,H.L.L. Le Louet
P185 MESSAGE FROM THE TOP: CHIEF PHARMACISTS VIEWS OF ADVERSE DRUG REACTIONS REPORTING.A.R. Cox, J.F. Marriott, K.A. Wilson, R.E. Ferner
P190 PILOT PROGRAM ACTIVITY COSMETIC-VIGILANCE COSMETIC-SURVEILLANCE ACTIVITY: INQUIRY ABOUT COSMETICS ADVERSE REACTIONS BETWEEN QUESTIONNAIRE IN FIVE PHARMACIES OF NAPLES.C.D.G. Di Giovanni Carmen, L.S. Lidia Sautebin,V.A. Vincenzo Arcoraci, L.G. Loredana
P195 DRUGS AND DEAFNESS: A PHARMACOEPIDEMIOLOGICAL CASE/ NON CASE STUDYE. Divoux, C. Remblier, M.C. Perault
P205 ADVERSE EFFECTS IN HIV INFECTED PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) RECEIVING ANTIRETROVIRAL TREATMENT AND THE TREATMENT OF TUBERCULOSIS INFECTIONJ. Dragovic, L.J. Djordje Jevtovic
P215 LIVER TOXICITY OF LOPINAVIR/RITONAVIR-CONTAINING REGIMENS IN HIV-INFECTED PATIENTS WITH OR WITHOUT HEPATITIS C VIRUS (HCV) CO-INFECTIONJ. Dragovic, L.J. Djordje Jevtovic
P220 LOPINAVIR/RITONAVIR VS. INDINAVIR/RITONAVIRIN HIV INFECTED PATIENTS: IMMUNO-VIROLOGICAL OUTCOME AND SIDE EFFECTSJ. Dragovic, L.J. Djordje Jevtovic
P225 LOW DOSE STAVUDINE: AS EFFECTIVE AS STANDARD DOSE BUT LESS SIDE EFFECTSJ. Dragovic, L.J. Djordje Jevtovic
P230 HOIGNE SYNDROME: CASE REPORTS AND MECHANISM OF PATHOGENESISS. El Aïdli, A. Zaïem, R. Daghfous, S. Sraïri, A. Klouz,M. Lakhal, M.H. Loueslati, C. Belkahia
P235 FAILURE OF ORAL CONTRACEPTIVES DURING THE USE OF HYPERICUM-CONTAINING DRUGSJ. Ericsson, R. Savage, M. Farah, R.H.B. Meyboom
P240 PHARMACIST’S ATTITUDES AND BEHAVIOUR RELATED TO REPORTING ADVERSE DRUG REACTION. A CASE-CONTROL STUDY IN PORTUGAL. M.T.F.H.Ferreira Herdeiro, F.A. Figueiras, P.M.M. Pinto, P.J.J. Polónia
P250 PATIENT EXPERIENCE REPORTS CAN HELP IMPROVE THE QUALITY OF EPILEPSY TREATMENTE.H. Fietjé, A.C.G. Egberts, T. Tempels, R.H.B. Meyboom
P255 NEUROPSYCHIATRIC ADVERSE DRUG REACTIONS IN GENERAL PRACTICEL. Galatti, S.E. Giustini, A. Sessa, G. Polimeni, F. Salvo,E. Spina, A.P. Caputi
P260 CASE REVIEW OF COX-2 SPECIFIC INHIBITORS RELATED ADRS RETRIEVED ROM THE DATABASE OF THE NATIONAL ADVERSE DRUGS REACTION REPORTING SYSTEM IN TAIWANC.S. Gau, Y.T.Y. You
P275 SURVEY ON TEENAGERS' SELF-MEDICATIONV. Gras-Champel, A.S. Lemaire-Hurtel, S. Lefevre-Skil,H. Masson, M. Andréjak
P285 MISUSE OF EMERGENCY CONTRACEPTION PILL?F. Haramburu, M.L. Laroche, C. Metge,G. Miremont-Salamé, B. Bégaud, F. Haramburu
P290 USE OF COMPLEMENTARY OR ALTERNATIVE PRODUCTS IN CANCER PATIENTSF. Haramburu, E. Apretna, C. Baillot-Hadjaj,G. Miremont-Salamé, C. Donamaria, M. Pommier,B. Hoerni, N.D. Moore, B. Bégaud, F. Haramburu
P300 ADVERSE UNEXPECTED EFFECT: IMPROVEMENT OF A PSORIASIS WITH BUPROPIONS. Havet, J.Y. Schlienger, A. Molia, M.L. Germain,T. Trenque
P305 FACTITIOUS HYPOGLYCAEMIA ASSOCIATED WITHSULPHONYLUREA DRUGS IN FRANCE DURING THREE YEARS.S. Havet, G. Hoizet, A. Molia, M.L. Germain, T. Trenque
P310 ADVANCES OF ADR REPORTING SYSTEM IN TAIWAN AND CASE REVIEW OF ANTIDEPRESSANTS FROM ADR DATABASEY.W. Huang, C.S. Gau, C.W. Hsu, H.C. Yen, H.P. Wang
P315 CENTRAL NERVOUS SYSTEM ADVERSE REACTION INDUCED BY CEFEPIME IN A FEMALE HEMODIALYSIS PATIENT - A CASE REPORTM. Huic, I. Francetic, M. Mayer, J. Pasini, M. Bilusic,V. Macolic Sarinic, I. Bakran
P325 IMMUNE AGRANULOCYTOSIS AND CLARITHROMYCINP. Jacobs, A. Conforti, L. Wood, A.K. Kiuru,G.O. Jones, D. Woolf
16
P330 FOLLOW-UP STUDY USING TDM AND PHARMACOGENETIC TESTING AS TOOLS IN PHARMACOVIGILANCEE. Jaquenoud Siro, C.B. Eap, P. Baumann
P340 VIGIMED, AN INTERNATIONAL DRUG SAFETY E-MAIL DISCUSSION GROUPK. Johansson, R.H.B. Meyboom, B. Hellman, S. Olsson
P345 COOPERATION BETWEEN THE NATIONAL PHARMACOVIGILANCE CENTRE AND REGISCAR IN THE NETHERLANDS: MUTUAL PROFITABLEJ.S. Kabel, E.P. Puijenbroek, J.N. Bouwes Bavinck
P350 CLINICAL TRIALS OF MEDICINAL PLANTS: BIBLIOGRAPHICAL REVIEW (1980-2000) AND METHODOLOGIC ANALYZESK. Kamagate, H. Die-Kacou, E. Balayssac,J.C. Yavo P.T. Daubret, K.A. Kakou, V.M. Gboignon
P360 SAFETY PROFILE OF PIOGLITAZONE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYR.K. Kasliwal, L. Wilton, S.A.W. Shakir
P365 SAFETY PROFILE OF ROSUVAST-ATIN AS USED IN GENERAL PRACTICE IN ENGLAND: INTERIM RESULTS OF A PRESCRIPTION-EVENT MONITORINGSTUDYR.K. Kasliwal, L. Wilton, S.A.W. Shakir
P370 GENERALIZED TONIC-CLONIC SEIZURES AND PROPOFOLS. Kastalli, S. El Aïdli, R. Daghfous, S. Trabelsi, S. Srairi, A. Klouz, M. Lakhal, M.H. Loueslati, C. Belkahia
P375 GINGIVAL HYPERPLASIA INDUCED BY CYCLOSPORINE IN RENAL TRANSPLANTY. Khabbal, D. Soussi Tanani, M. Ait El Cadi,M. Aghrouch, N.O. Ouzeddoun, Y. Cherrah
P380 ADVERSE DRUG EVENTS AND POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLYM.L. Laroche, Y. Nouaille, J.P. Chaemes, T. Dantoine,L. Merle
P385 ARE GENERICS AS SAFE AS THEIR PRINCEPS COUNTERPARTS ?M.L. Laroche, Y. Nouaille, L. Merle
P390 INCIDENCE RATES OF CEREBROVASCULAR ACCIDENTS AND TRANSIENT ISCHAEMIC ATTACKS WITH ANTIPSYCHOTIC DRUGS IN GENERAL PRACTICE IN ENGLAND: A RETROSPECTIVE ANALYSIS OF PRESCRIPTION-EVENT MONITORING (PEM) DATA.D. Layton, S. Harris, L.V. Wilton, S.A.W. Shakir
P395 SAFETY PROFILE OF DESLORATADINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDY.D. Layton, L.V. Wilton, S.A.W. Shakir
P400 SAFETY PROFILE OF LEVOCETIRIZINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDY.D. Layton, A. McMillan, L.V. Wilton, S.A.W. Shakir
P405 IS THE DHE - TRIPTANS CONTRAINDICATION STILL JUSTIFIED?H.L. Lelouet, H. Allain, L. Guesnier
P410 DOMESTIC SELF-MEDICATION: AN ITALIAN ATTITUDINAL SURVEYR. Leone, I. Meneghelli, T. Camerlengo, S. Segat,U. Moretti, G.P. Velo
P420 ASSESSMENT OF PROLONGED-RELEASE TRAMADOL EFFICACY AND SAFETY IN GENERAL MEDICAL PRACTICE: A PROSPECTIVE OBSERVATIONAL STUDY.P. Lora Aprile, G. Trifiro, G. Mazzaglia, E. Sessa,O. Brignoli, A.P. Caputi
P425 APOMORPHINE GENERALLY WELL TOLERATED IN THE TREATMENT OF ERECTILE DYSFUNCTION: RESULTS OF A PRESCRIPTION-EVENT MONITORING (PEM) STUDY.K.M. Maclennan, K.M. Maclennan, A. Boshier,L.V. Wilton, S.A.W. Shakir
P430 SAFETY PROFILE OF REPAGLINIDE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYV. Marshall, L.V. Wilton, S.A.W. Shakir
P440 TRAINING INITIATIVES IN VACCINE SAFETY MONITORING THROUGH THE WORLD HEALTH ORGANIZATION (WHO) GLOBAL TRAINING NETWORK (GTN)U. Mehta, A. Bentsi-Enchill, D. Lei, P. Duclos,L. Belgharbi, M. Zaffran, C. Belkahia, S. Peiris,T. Bektimirov, P.I. Folb
P445 ADVERSE EVENTS TO HERBAL PREPARATIONS: ALLERGIC REACTIONS TO PROPOLIS.FMI Menniti-Ippolito, F Menniti-Ippolito, G Mazzanti,F Firenzuoli, A Bianchi, C Santuccio, R Raschetti
P460 ACHIEVING EXCELLENCE IN AVENTIS UK PHARMACOVIGILANCEN. Mihajlovic- Gojkovic, J. Savage, M. Norwood,E. Mundy, A. McPherson, G. Braga, R. Richardson, P. Kon
17
P465 ADVERSE EVENTS ASSOCIATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): A SURVEY IN HIV-INFECTED POPULATION OVER18-MONTH PERIODA. Molia, C. Strady, S. Havet, I. Beguinot, C. Rouger,J.L. Berger, A. Waldner, M.L. Germain, T. Trenque
P470 AGRANULOCYTOSIS DURING TREATMENT WITH CYAMEMAZINE AND VENLAFAXINEA. Molia, A.M. Blaise, B. Kolb, S. Havet, M.L. Germain,T. Trenque
P475 PHARMACOVIGILANCE PLANS FOR EMERGING ONCOLOGY COMPOUNDSS.R. Morgan, A.J. Hudson, H.D.J. Snow
P476 CHOLESTATIC HEPATITIS WITH FLUCLOXACILLIN: UK SPONTANEOUS REPORTS 12 YEARS ONJ N S Moseley, S Wark, J Woolley
P477 PRELIMINARY COMPARISON OF 2 SIGNAL DETECTION METHODOLOGIES IN THE UK REGULATORY AUTHORITY SPONTANEOUS ADR DATABASEJ N S Moseley, E Heeley, S Ekins-Daukes, S Evans
P485 VACCINE ASSOCIATED ADVERSE EVENT SURVEILLANCE (VAAES) AND QUALITY ASSURANCE (QA)
J.N. Nkanza, W. Walop
P505 REPORTS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FROM A PRESCRIPTION EVENT MONITORING STUDY OF YASMIN® IN ENGLANDH.M. Pearce, D. Layton, L.V. Wilton, S.A.W. Shakir
P510 SAFETY PROFILE OF SIBUTRAMINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYH.M. Pearce, L.V. Wilton, S.A.W. Shakir
P515 NEUROPSYCHIATRIC DISORDERS INDUCED BY ISOTRETINOIN. ANALYSIS OF CASES REPORTED IN THE FRENCH PHARMACOVIGILANCE DATABASE AND REVIEW OF THE LITERATUREP. Peyrière, P. Recolin, M.A. Thompson, J.P. Blayac,D. Hillaire-Buys
P520 SSRI-INDUCED HEPATOXICITY: REVIEW OF DATA FROM THE FRENCH PHARMACOVIGILANCE DATABASE AND LITERATURE.V. Pinzani, D. Hillaire-Buys, M. Creus-Findeling,M.L. Hemery, G. Pageaux, D. Larrey, J.P. Blayac
P540 CLINICO-TOXICOLOGICAL ASSESSMENT OF ATYPICAL ANTIPSYCHOTICSD. Prasa, G. Hüller, H. Hentschel
P555 A CASE REPORT OF RHABDOMYOLYSIS WITH PENTAMIDINE: SIGNAL REPLICATION UTILIZING A NEW PHARMACOVIGILANCE TOOL UNDER INVESTIGATION.L. Reich, M. Hauben
P560 POSTMARKETING SURVEILLANCE OF POTENTIALLY FATAL REACTIONS TO ONCOLOGY DRUGS: FINDINGS FROM TWO DATA MINING ALGORITHMS.L. Reich, M. Hauben, S. Chung
P565 USE OF A NEW PHARMACOVIGILANCE TOOL UNDER INVESTIGATION TO EVALUATE AN UNEXPECTED STRUCTURE-ADVESE EFFECT RELATIONSHIP INITIALLY IDENTIFIED BY LABORATORY RESEARCHL. Reich, M. Hauben
P570 AUTISM AND PEDIATRIC VACCINESA.R.V. - Roque Valdés
P580 FLUOROQUINOLONE (FQ)-ASSOCIATED ANAPHYLAXIS IN SPONTANEOUS ADR REPORTS: OCCURRENCE AFTER FIRST USE AND APPARENT DIFFERENCES IN REPORTING RATES BETWEEN FQSB. Sachs, S. Erdmann, S. Riegel, D. Schichler, H. Merk,J. Beckmann, A. Barger
P585 PRESCRIPTION ERRORS IN PRIMARY CARE: TYPES, DETERMINANTS AND THERAPEUTIC IMPLICATIONSR.P. Sequeira, T.M. Alansari, K.A. Alkhaja
P595 DEVELOPMENT OF PLANTS TOXICOLOGY TWO DATABASESS. Skalli, R. Benkirane, R. Soulaymani
P615 PHARMACOVIGILANCE OF CHILDHOOD VACCINATION IN ITALY, 2001-2003.S. Spila Alegiani, L. Pastore Celentano, C. Santuccio,B. Caffari, R. Raschetti, S. Salmaso, G. Traversa,M.L. Ciofi degli Atti
P620 HYPERSENSITIVITY TO GLUCOCORTICOIDS.S. Sraïri, S. El AÏdli, R. Daghfous, A. Klouz, S. Kastalli,A. Zaïem, M. Lakhal, M.H. Loueslati, C. Belkahia
P625 WHO SIGNALS FROM 1998 TO 2001 - A FOLLOW-UPK. Star, M. Ståhl, J. Strandell, M. Pettersson, M. Lindquist
P635 AGRANULOCYTOSIS ASSOCIATED TO CARBIMAZOLE : A CASE REPORTA. Tebaa, D. Soussi-Tanani, Y. Khabbal, N. Smires,S. Serragui, R. Soulaymani
P640 COMPLEMENTARY MEDICINES: CASE REPORTS OF ADVERSE REACTIONS DUE TO ADULTERATIONK.N. Ting, P.S. Ang, B.H. Tan, M.Y. Low,B.C. Bloodworth, C.L. Chan
18
P645 DRUGS INDUCED BULLOUS TOXIDERMIA NOTIFIED TO THE TUNISAN PHARMACOVIGILANCE CENTRES. Trabelsi, S. El Aïdli, S. Kastalli, R. Daghfous, M. Lakhal,M.H. Loueslati, C. Belkahia
P650 NEUROLOGICAL DISORDERS ASSOCIATED WITH VACCINE USE: A PROSPECTIVE CASE-CONTROL STUDYG. Traversa, A. Capuano, R. Da Cas, F. Menniti-Ippolito, R. Rossi, S. Renna, P. Barabino, N. Pirozzi, C. Cecchetti, V. Iori, U. Raucci, G. Viviano
P655 ADVERSE DRUG EVENTS IN EMERGENCY DEPARTMENT POPULATION: A PROSPECTIVEITALIAN STUDYG. Trifiro, G. Calogero, F. Menniti Ippolito,M. Cosentino, R. Giuliani, A. Conforti, M. Venegoni,G. Mazzaglia, A.P. Caputi
P665 POSTMARKETING SURVEILLANCE OF RISEDRONATE IN FILIPINO PATIENTS WITH OSTEOPOROSISC.I. Valencia, J.N. Sarol, J.R. Dimaano, N.C. Cruz, Actonel Study Group
P670 NON STEROIDAL ANTI-INFLAMMATORY AGENT AND EDEMA : RESPONSIBLE OF HOSPITALIZATIONIN 50% OF CASES.V.R. Valnet Rabier, C. Legalery, J.P. Kantelip
P675 CHALLENGES FOR A JAPANESE COMPANY IN EUROPEJ.W. van der Velden
P680 THE DRUG SAFETY UNIT IN A CROJ.W. van der Velden
P685 LOW MOLECULAR WEIGHT HEPARINS. REPORTING RATE INCIDENCE AND PROFILE OF ADVERSE REACTIONS REPORT IN SPAIN.E. Vera, V. García del Pozo, J. García del Pozo,L.H. Martín Arias, A. Velasco, A. Carvajal
P690 SUICIDAL ATTEMPTS IN YELLOW CARDS REPORT ON THE SPANISH PHARMACOVIGILANCE SYSTEME. Vera, V. García del Pozo, J. García del Pozo,L.H. Martín Arias, A. Velasco A. Carvajal
P695 DRUG-INDUCED HYPONATREMIAS (DIH): A 5-YEAR SURVEY OF THE FRENCH PHARMACOVIGILANCE DATABASET. Vial, A. Roudon, P. Auriche, N. Bernard, C. Payen,J. Descotes
P700 MEDICATION ERRORS: EXPERIENCE OF A POISON CENTERT. Vial, C. Pulce, C. Boluda-Garayt, S. Merindol,C. Bavuz, C. Payen, P. Frantz, J. Descotes
P705 SEVERE TOXICITY ASSOCIATED WITH A DRUG CONTAINING DIETHYLENE GLYCOL ETHYL-ETHER(DEGEE) AS AN EXCIPIENT: REPORT OF 6 CASEST. Vial, P. Harry, H. Eftekhari, H. Jantzem,A.P. Jonville-Bera, B. Mosquet, C. Payen, J. Descotes
P710 THE IMPORTANCE OF REPORTING MEDICATION ERRORS WITH VACCINESW. Walop
P715 ELUCIDATING THE MECHANISM OF LITHIUM ACQUIRED NEPHROGENIC DIABETES INSIPIDUSI. Wilting, R. Baumgarten, K.L.L. Movig,J.H.M. van Laarhoven, A.J. Apperloo, W.A. Nolen,E.R. Heerdink, A.C.G Egberts
P720 A COHORT STUDY TO MONITOR THE MANAGEMENT AND OUTCOMES OF SELECTED ADVERSE DRUG REACTIONS WITH CARVEDILOL WHEN USED FOR CARDIAC FAILURE IN ENGLANDL.V. Wilton, B. Aurich Barrera, V. Marshall, S.A.W. Shakir
P725 SAFETY PROFILE OF TIOTROPIUM USED IN GENERAL PRACTICE IN ENGLAND: INTERIM RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYL.V. Wilton, S.A.W. Shakir
P750 TITLE: THE IMPACT OF RISK COMMUNICATION STRATEGIES ON NEFAZODONE PRESCRIPTION TRENDS IN CANADA BETWEEN 1994 AND 2003J. Zhang, V. Hogan, D. Clapin
P755 DRUG SURVEILLANCE AND INFORMATION CENTER: EFFICACY ON ALERT SIGNAL DETECTIONM. del Zompo, M.E. Stochino, R. de Lisa, C. Asuni,G. Severino, C. Chillotti, R. Ardau
S O C I A L P R O G R A M M E
The Local Organising Committee would like to acknowledge the contribution ofAstraZeneca and Janssen-Cilag towards the welcome reception.
W E L C O M E R E C E P T I O N ( W E D 6 T H O C T O B E R 2 0 0 4 )
18.30 - 20.30
The Welcome Reception will take place in the Atrium of the Chester Beatty Library, situated
in the Clock Tower Building of Dublin Castle. The Library was recently voted ‘European
Museum of the Year 2002’, the first occasion for Ireland. Tour guides will be available on
the night to answer any questions you may have on the collections. The library is situated
adjacent to Dublin Castle on the map below.
The Chester Beatty library is approximately a 20-25 min walk from the Conference Venue,
or is a short trip in a taxi.
Bus transportation will be arranged from the meeting venue to the welcome reception.
C O N F E R E N C E D I N N E R ( T H U R S 7 T H O C T O B E R 2 0 0 4 )
19.00 - 22.30
The official Conference Dinner will take place in the Old Jameson Distillery in Dublin’s
historic Smithfield. Originally built in 1780, the whiskey Distillery has been recreated to its
former world-renowned glory and is now an award-winning visitor attraction. A guided tour
will be provided on the night and guests will be treated to the lively ‘Shindig’ including
musicians, a five-course meal and optional whiskey tasting.
Bus transportation will be arranged from the meeting venue to the conference dinner.
Please note that smoking is not permitted in either of these venues at any time.
Please see map on page (iii) for location of the above venues.
19
G E N E R A L I N F O R M A T I O N O N I R E L A N D
B A C K G R O U N D I N F O R M A T I O NClimate:
The weather in Ireland in October is generally mild (9-18oC) and usually pleasant, but may be
showery.
Dublin – Local Attractions:• Trinity College, 0.5 mile. S• National Concert Hall, 1 block S• National Art Gallery, 0.5 mile. S• Natural History Museum, 0.5 mile. S• St. Stephen's Green, 0.5 block S• Leinster House, 0.5 mil. S• Temple Bar, 1 km. N
Visit www.ireland.ie for more information
Money
The unit of currency used in Ireland is the euro (€). One euro consists of one hundred cent.
Notes are €5, €10, €20, €50, €100, €200 and €500. Coins are €2, €1, 50c, 20c, 10c, 5c, 2c and 1c.
Credit CardsAny credit cards that bear the Visa, MasterCard or American Express symbol will be widelyaccepted in Ireland. Visitors with other cards should ask in advance or see if that card is ondisplay where they wish to use it.
BanksOpening HoursMonday through Friday: 10.00 a.m. – 4.00 p.m. Thursday: 10.00 a.m. – 5.00 p.m.
ATM (cash) machines are located at most banks and accept most credit and debit cards.American Express: Opening HoursMonday – Saturday: 9.00 a.m. – 5.00 p.m.
Thomas Cook Ltd. Opening HoursMonday – Friday: 09.00 a.m. – 5.00 p.m.Saturday: 09.00 a.m. – 12.00
Post Office Opening HoursMonday – Friday 09.30 a.m. – 1.00 p.m. 2.15 p.m. – 5.30 p.m.
20
Electricity
The Irish electrical current is 220 volts. The most commonly used plugs are 3-pin flat. As
Irish voltage is different to US/Canadian voltage, you will need to bring/buy a voltage
converter if you are bringing electrical appliances. Voltage converters are available from
most electrical stores.
Emergency Services – Police, Fire, Ambulance:
Tel: 112 or 999.
These numbers are free of charge but should only be used in cases of genuine emergency.
On answer, state which service you require, wait to be connected to that service, then
clearly state the location of where the assistance is required.
In the case of a vehicle breakdown:
Automobile Association (AA)
Tel: 1800 66 77 88
RAC Motoring Service
Tel: 1800 535 005
Telecommunications
Pay Phones
Pre-paid phone cards are widely available and are both convenient and effective to use.
Telephone Enquiries
Directory Enquiries: 11811 (for any number you need within Ireland & Northern Ireland
11818 (for any number you need outside Ireland
Operator Assistance: 10 (Ireland, Northern Ireland & Britain)
114 (International)
Telephone Codes
If calling Republic of Ireland from abroad all telephone numbers must be prefixed with
00 353 (drop the first 0 of the local code)
International access code from Ireland is always 00 followed by country code, area code etc.
Smoking ban within the Republic of Ireland
Ireland introduced a blanket ban on smoking in all work places to protect public health
and reduce the incidences of smoking-related illness in March 2004.
No smoking is allowed in public areas – this includes all bars, nightclubs and restaurants.
Although hotel bedrooms will be exempt from the ban, it applies to all other areas within
hotels.
21
N O T E S
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
..........................................................................................................................................................................................
22